Top Page
Haleon PLC
(LSE:HLN)
Haleon PLC (HLN) vs. iShares MSCI United Kingdom ETF (EWC)
Haleon PLC Business Overview & Revenue Model
Haleon PLC Earnings Call Summary
Haleon PLC Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.02B | 11.23B | 11.30B | 10.86B | 9.54B | 9.89B |
| Gross Profit | 6.81B | 6.82B | 6.75B | 6.73B | 5.95B | 5.91B |
| EBITDA | 2.79B | 2.68B | 2.67B | 2.68B | 2.21B | 2.19B |
| Net Income | 1.52B | 1.44B | 1.05B | 1.06B | 1.39B | 1.15B |
Balance Sheet | ||||||
| Total Assets | 31.83B | 34.31B | 34.05B | 34.81B | 34.45B | 34.13B |
| Cash, Cash Equivalents and Short-Term Investments | 676.00M | 2.19B | 1.04B | 684.00M | 414.00M | 334.00M |
| Total Debt | 8.54B | 10.10B | 9.46B | 10.44B | 991.00M | 487.00M |
| Total Liabilities | 15.83B | 18.09B | 17.33B | 18.36B | 7.97B | 7.91B |
| Stockholders Equity | 15.94B | 16.17B | 16.61B | 16.33B | 26.36B | 26.11B |
Cash Flow | ||||||
| Free Cash Flow | 931.00M | 1.98B | 1.76B | 1.74B | 1.06B | 1.09B |
| Operating Cash Flow | 1.03B | 2.30B | 2.10B | 2.06B | 1.36B | 1.41B |
| Investing Cash Flow | -76.00M | 528.00M | -134.00M | -8.78B | -33.00M | 1.03B |
| Financing Cash Flow | -2.52B | -1.54B | -1.57B | 6.91B | -1.24B | -2.44B |
Haleon PLC Technical Analysis
Haleon PLC Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £3.89B | 13.61 | 15.66% | 3.61% | 3.73% | 27.13% | |
71 Outperform | £31.87B | 21.29 | 9.35% | 1.57% | -2.12% | 42.10% | |
57 Neutral | £171.09M | -7.00 | 2.83% | 2.10% | 8.74% | -166.50% | |
56 Neutral | £518.95M | -11.27 | ― | ― | 4.50% | 74.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Haleon PLC Corporate Events
Haleon PLC announced the release of its Q3 trading statement for 2025, highlighting its financial performance and strategic initiatives. The statement is accessible on the company’s website and through the Financial Conduct Authority’s National Storage Mechanism. A presentation for analysts and shareholders, led by CFO Dawn Allen, will provide further insights into the company’s operations and future outlook, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £3.80 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC is conducting a clinical study titled Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice. The study aims to evaluate the effectiveness of a new dentifrice containing stannous fluoride and potassium nitrate in reducing dentin hypersensitivity compared to other dentifrices over an 8-week period.
Haleon PLC is conducting a clinical study titled ‘A 12-Week Randomized, Controlled, Single-Blind, Clinical Study Investigating the Efficacy of an Experimental Toothpaste Containing Stannous Fluoride in Improving Gingival Health.’ The study aims to evaluate the effectiveness of a new toothpaste containing 0.454% Stannous Fluoride in enhancing gingival health and reducing plaque compared to a standard fluoride toothpaste in individuals with gingivitis.
Haleon PLC has announced the notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities (PDMRs) under the UK Market Abuse Regulation. The transactions involve the acquisition of Partnership Shares and the award of Matching Shares under the company’s Share Reward Plan by Adrian Morris, General Counsel, and Tamara Rogers, Chief Marketing Officer. This move reflects the company’s ongoing commitment to aligning managerial interests with shareholder value, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £3.80 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the appointment of Tracy Clarke, a Non-Executive Director, to the board of Inchcape PLC, effective December 31, 2025. This strategic move may enhance Haleon’s industry positioning by fostering stronger leadership connections and potentially influencing future collaborations or market strategies.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £3.80 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC has completed the final tranche of its share buyback programme, purchasing 1,561,229 ordinary shares to be held as treasury shares. This move finalizes a series of buybacks initiated earlier in the year, which included shares repurchased from Pfizer, totaling 175,806,525 shares. The completion of this programme is a strategic step for Haleon, impacting its capital structure and potentially enhancing shareholder value.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £3.80 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced that as of September 30, 2025, it has issued a total of 8,952,353,648 ordinary shares, with 44,400,783 held as treasury shares. This results in 8,907,952,865 shares with voting rights, which shareholders and others with notification obligations should use as the denominator for calculating their interest in the company. This update is crucial for stakeholders to comply with the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £3.80 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 1,500,000 ordinary shares as part of its share buyback program. The shares will be held as treasury shares, impacting the company’s share capital and voting rights. This move is part of Haleon’s strategy to manage its capital structure and could influence shareholder decisions regarding their interests in the company.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £3.80 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 1,996,340 ordinary shares as part of its ongoing share buyback program. This transaction, completed on September 29, 2025, is part of the second tranche of the program announced earlier in July. The purchased shares will be held as treasury shares, impacting the company’s share capital and voting rights. This move is likely aimed at consolidating shareholder value and optimizing capital structure, reflecting positively on Haleon’s market positioning.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £3.80 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 1,996,340 ordinary shares as part of the second tranche of its share buyback program. The purchased shares will be held as treasury shares, impacting the company’s total share capital and voting rights. This move is part of Haleon’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £3.80 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the acquisition of ordinary shares by key managerial personnel through dividend reinvestment. This transaction, involving figures such as the CEO and regional presidents, underscores the company’s commitment to aligning management interests with shareholder value, potentially impacting its market perception positively.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £3.80 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 2,318,700 ordinary shares as part of its ongoing share buyback program. The shares will be held as treasury shares, impacting the company’s share capital and voting rights. This move is part of Haleon’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £3.80 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 3,251,858 ordinary shares as part of its ongoing share buyback program. This move is part of the second tranche of the program, initially announced in July 2025. The shares will be held as treasury shares, impacting the company’s share capital and voting rights. This strategic financial maneuver is likely aimed at enhancing shareholder value and optimizing capital structure, reflecting Haleon’s commitment to maintaining a robust financial position.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £3.80 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC has announced the purchase of 5,150,000 ordinary shares as part of the second tranche of its share buyback program. This move is intended to strengthen the company’s financial position by holding the purchased shares as treasury shares, impacting the number of shares with voting rights and potentially influencing shareholder decisions.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £3.80 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 5,150,000 ordinary shares as part of its share buyback program, which commenced on July 31, 2025. The shares will be held as treasury shares, impacting the company’s share capital and voting rights. This move is part of Haleon’s strategy to manage its capital structure effectively, potentially enhancing shareholder value and signaling confidence in the company’s financial health.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £3.80 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities (PDMRs) in compliance with the UK Market Abuse Regulation. The transactions involved the acquisition of ordinary shares through dividend reinvestment by Tamara Rogers, Chief Marketing Officer, and Alan Stewart, Independent Non-Executive Director, on the London Stock Exchange. This announcement highlights the company’s adherence to regulatory requirements and transparency in its operations, potentially impacting stakeholder trust and market perception.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £380.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 4,150,000 ordinary shares as part of the second tranche of its share buyback program. The company plans to hold these shares as treasury shares, impacting its registered share capital and the number of shares with voting rights. This move is part of Haleon’s strategic financial management, potentially affecting shareholder interests and market positioning.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £380.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 4,314,000 ordinary shares as part of the second tranche of its share buyback program. This strategic move aims to consolidate the company’s share capital and potentially enhance shareholder value by holding the purchased shares as treasury shares. Following this transaction, Haleon’s registered share capital comprises 8,952,353,648 ordinary shares, with 18,887,545 held as treasury shares, affecting the number of shares with voting rights and shareholder notifications under regulatory rules.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £380.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC has announced the purchase of 5,214,540 ordinary shares as part of the second tranche of its share buyback program. This move is aimed at consolidating its capital structure by holding the purchased shares as treasury shares, impacting the company’s share capital and voting rights. The transaction reflects Haleon’s strategic financial management and could influence shareholder decisions under the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £380.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 5,357,044 ordinary shares as part of the second tranche of its share buyback program. The company plans to hold these shares as treasury shares, impacting its registered share capital and the number of shares with voting rights. This move reflects Haleon’s strategic financial management and may influence shareholder decisions regarding their interests in the company.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £380.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 1,500,000 ordinary shares as part of the second tranche of its share buyback program. The shares will be held as treasury shares, impacting the company’s share capital and voting rights. This move reflects Haleon’s strategic financial management and may influence shareholder decisions under the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £398.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 997,991 ordinary shares as part of the second tranche of its share buyback program. This move is likely to impact the company’s share capital, with 23,788 shares being canceled and 974,203 held as treasury shares, potentially influencing shareholder voting rights and market perception.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £398.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced that as of August 31, 2025, it has issued a total of 8,959,221,411 ordinary shares, with 3,880,205 held as treasury shares. This leaves 8,955,341,206 shares with voting rights, a figure crucial for shareholders and others with notification obligations under the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £400.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 2,062,463 ordinary shares for cancellation as part of its ongoing share buyback program. This transaction is part of the second tranche of the program, initially announced in July 2025, and reflects the company’s strategic efforts to manage its capital structure. Following this purchase, the company’s registered share capital consists of 8,959,221,411 ordinary shares, with 8,955,341,206 shares having voting rights. This move is likely to impact Haleon’s market positioning by potentially increasing shareholder value and reflects a commitment to returning capital to shareholders.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £400.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC has announced the purchase of 1,504,400 ordinary shares for cancellation as part of the second tranche of its share buyback program. This move is expected to impact the company’s share capital and voting rights, with implications for shareholders under the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £350.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 1,600,000 ordinary shares for cancellation as part of its ongoing share buyback program. This transaction, which took place on August 15, 2025, is part of the second tranche of the program and reflects the company’s commitment to enhancing shareholder value. Following this purchase, the company’s registered share capital stands at 8,973,306,495 ordinary shares, with 8,969,426,290 shares carrying voting rights, which may impact shareholder notifications under the FCA’s rules.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £350.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC has announced the purchase and cancellation of 1,517,728 ordinary shares as part of its ongoing share buyback program. This transaction is part of the second tranche of the program, reflecting the company’s commitment to optimizing its capital structure and potentially enhancing shareholder value. The company’s registered share capital now stands at 8,981,923,508 ordinary shares, with 8,978,043,303 shares carrying voting rights. This move may impact shareholders’ interests and align with regulatory requirements under the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £350.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 1,511,000 ordinary shares for cancellation as part of its share buyback program. This move is part of the second tranche of the program, initially announced on July 31, 2025, and reflects the company’s strategy to enhance shareholder value. The transaction impacts the company’s registered share capital, now totaling 8,983,441,236 ordinary shares, with 3,880,205 held as treasury shares. This adjustment in share capital may influence shareholder notifications under the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £350.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced a notification regarding the vesting of shares for Ed Petter, Chief Corporate Affairs Officer, under the company’s Share Value Plan. This transaction, which compensates for incentives forfeited from his previous employment, reflects Haleon’s commitment to aligning executive remuneration with company performance. The transaction involved the acquisition and partial disposal of shares to cover tax liabilities, indicating a structured approach to executive compensation and compliance with UK Market Abuse Regulations.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £350.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC has announced the purchase and cancellation of 1,418,324 ordinary shares as part of its ongoing share buyback program. This move is part of the second tranche of the program, initially announced on July 31, 2025, and reflects the company’s commitment to enhancing shareholder value. The transaction impacts the company’s registered share capital, reducing the number of ordinary shares with voting rights, which stakeholders can use to assess their interests under regulatory guidelines.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £350.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 1,281,000 ordinary shares for cancellation as part of its share buyback program. This move is part of the second tranche of the program, initially announced on July 31, 2025. The transaction affects the company’s share capital, reducing the number of shares with voting rights to 8,982,490,355. This strategic step is likely to impact shareholder interests and reflects Haleon’s commitment to optimizing its capital structure.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £350.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced that as of July 31, 2025, the total number of shares issued is 8,987,651,560, with 3,880,205 held as treasury shares. This results in 8,983,771,355 ordinary shares with voting rights, a crucial figure for shareholders and others with notification obligations under the FCA’s Disclosure Guidance and Transparency Rules. This update is significant for stakeholders as it impacts the calculation of notifiable interests in the company.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £3.70 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the purchase of 881,993 ordinary shares for cancellation as part of its share buyback program. This transaction impacts the company’s share capital, reducing the number of shares with voting rights and potentially affecting shareholder interests under the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC’s recent earnings call presented a mixed sentiment, highlighting both positive developments and significant challenges. The company showcased successful innovations and improved gross margins, alongside strong performance in Oral Health. However, it also faced considerable headwinds in North America, particularly with inventory pressures and declines in the Smokers’ Health segment. Despite these challenges, Haleon is implementing promising strategies to address these issues.
Haleon PLC announced the commencement of a second tranche of its share buyback program, aiming to purchase up to £280 million worth of shares. This move is part of a larger £500 million buyback initiative for 2025, with the goal of reducing the company’s share capital and fulfilling obligations under employee share plans. The buyback will be executed through an agreement with Citigroup Global Markets Limited, with trading decisions made independently of Haleon. This strategic financial maneuver is expected to impact Haleon’s market positioning by optimizing its capital structure and potentially enhancing shareholder value.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced its half-year results for 2025, revealing a 10% increase in the interim dividend to 2.2 pence per share, reflecting its policy to distribute approximately one-third of the prior year’s full-year dividend. This decision underscores Haleon’s commitment to growing its ordinary dividend in line with adjusted earnings, subject to market conditions and board approval. The results presentation by the CEO and CFO will be available online, followed by a Q&A session, indicating transparency and engagement with stakeholders.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £350.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.